colon cancer, lung cancer, gastric cancer, breast cancer, gynecologic cancer, pancreatic cancer
Conditions
Interventions
None listed
Sponsors
Medical Science Department Daiichi Sankyo Company, Limited.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1)20 years old or older at written informed consent. (2) Diagnosed with any one of the following: colorectal cancer, lung cancer (small cell lung cancer, and non-small cell lung cancer), gastric cancer, breast cancer, gynecological cancer (endmetrial cancer, cervical cancer, ovarian cancer, fallopian tube cancer, and peritoneal cancer), or pancreatic cancer (both initial and/or recurrence). Except active double cancer (synchronous double cancer, and metachronous double cancer with a disease-free period within 5 years) patients but patients with intramucosal cancer can be enrolled. (3) Planned to undergo drug therapy (chemotherapy, hormone therapy, targeted molecular therapy, and immune checkpoint inhibitor therapy), radiation therapy or surgery. For recurrence cases, patients who received drug therapy (chemotherapy, hormone therapy, targeted molecular therapy, and immune checkpoint inhibitor therapy), radiation therapy or underwent surgery at initial occurrence can be enrolled. (4) Carried out VTE screening (lower extremities venous ultrasound) within 2 months before enrollment and before the cancer treatment. If D-dimer value after the diagnosis of cancer is <=1.2 microgram/mL, VTE screening is not required. (5) Stage II to IV; for gynecological cancer, Stage I to IV and for lung cancer, Stage IB to IV. (6) Expected survival after enrollment must be >=6 months; for pancreatic cancer, >=3 months. (7) Eastern Cooperative Oncology Group (ECOG) Performance Status grade must be 0-2; for pancreatic cancer, 0-1. (8) Informed consent in writing given freely by the patients themselves for participation in the survey of this study.
Exclusion criteria
Exclusion criteria: A patient who is inappropriate as a subject of the study judged by investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| (1)Baseline frequency of intercurrent of VTE at the time of VTE screening (2)Observation period (one year) incidence of symptomatic VTE incidence of bleeding events | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of brain infarction/ systemic embolism Survival VTE related mortality rate and bleeding related mortality rate Brain infarction related mortality rate and systemic embolism related mortality rate | — |
Countries
Japan
Contacts
Public ContactSecretariat Cancer-VTE Registry
EPS Corporation Clinical Research Center
Outcome results
None listed